UCB gets rights to Synosia's SYN115 and SYN118; all rights later returned
UCB Group has optioned exclusive global rights to Synosia Therapeutics Inc.'s (neurology drug candidates) SYN115 and SYN118 for non-orphan indications. Both drug candidates are in Phase II for Parkinson's disease.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com